• Je něco špatně v tomto záznamu ?

Effect of metformin therapy on cardiac function and survival in a volume-overload model of heart failure in rats

Jan Benes, Ludmila Kazdova, Zdenek Drahota, Josef Houstek, Dasa Medrikova, Jan Kopecky, Nikola Kovarova, Marek Vrbacky, David Sedmera, Hynek Strnad, Michal Kolar, Jiri Petrak, Oldrich Benada, Petra Skaroupkova, Ludek Cervenka, Vojtech Melenovsky

. 2011 ; 121 (1) : 29-41.

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc12027089

Grantová podpora
NS10497 MZ0 CEP - Centrální evidence projektů

Advanced HF (heart failure) is associated with altered substrate metabolism. Whether modification of substrate use improves the course of HF remains unknown. The antihyperglycaemic drug MET (metformin) affects substrate metabolism, and its use might be associated with improved outcome in diabetic HF. The aim of the present study was to examine whether MET would improve cardiac function and survival also in non-diabetic HF. Volume-overload HF was induced in male Wistar rats by creating ACF (aortocaval fistula). Animals were randomized to placebo/MET (300 mg·kg(-1) of body weight·day(-1), 0.5% in food) groups and underwent assessment of metabolism, cardiovascular and mitochondrial functions (n=6-12/group) in advanced HF stage (week 21). A separate cohort served for survival analysis (n=10-90/group). The ACF group had marked cardiac hypertrophy, increased LVEDP (left ventricular end-diastolic pressure) and lung weight confirming decompensated HF, increased circulating NEFAs (non-esterified 'free' fatty acids), intra-abdominal fat depletion, lower glycogen synthesis in the skeletal muscle (diaphragm), lower myocardial triacylglycerol (triglyceride) content and attenuated myocardial (14)C-glucose and (14)C-palmitate oxidation, but preserved mitochondrial respiratory function, glucose tolerance and insulin sensitivity. MET therapy normalized serum NEFAs, decreased myocardial glucose oxidation, increased myocardial palmitate oxidation, but it had no effect on myocardial gene expression, AMPK (AMP-activated protein kinase) signalling, ATP level, mitochondrial respiration, cardiac morphology, function and long-term survival, despite reaching therapeutic serum levels (2.2±0.7 μg/ml). In conclusion, MET-induced enhancement of myocardial fatty acid oxidation had a neutral effect on cardiac function and survival. Recently reported cardioprotective effects of MET may not be universal to all forms of HF and may require AMPK activation or ATP depletion. No increase in mortality on MET supports its safe use in diabetic HF.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12027089
003      
CZ-PrNML
005      
20180308091505.0
007      
ta
008      
120816s2011 enk f 000 0#eng||
009      
AR
024    7_
$a 10.1042/cs20100527 $2 doi
035    __
$a (PubMed)21275906
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Beneš, Jan, $d 1983- $7 xx0221722 $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic; Center for Experimental Medicine, Institute for Clinical and Experimental Medicine (IKEM), Prague; Center for Cardiovascular Research, Prague, Czech Republic. jan.benes@ikem.cz
245    10
$a Effect of metformin therapy on cardiac function and survival in a volume-overload model of heart failure in rats / $c Jan Benes, Ludmila Kazdova, Zdenek Drahota, Josef Houstek, Dasa Medrikova, Jan Kopecky, Nikola Kovarova, Marek Vrbacky, David Sedmera, Hynek Strnad, Michal Kolar, Jiri Petrak, Oldrich Benada, Petra Skaroupkova, Ludek Cervenka, Vojtech Melenovsky
520    9_
$a Advanced HF (heart failure) is associated with altered substrate metabolism. Whether modification of substrate use improves the course of HF remains unknown. The antihyperglycaemic drug MET (metformin) affects substrate metabolism, and its use might be associated with improved outcome in diabetic HF. The aim of the present study was to examine whether MET would improve cardiac function and survival also in non-diabetic HF. Volume-overload HF was induced in male Wistar rats by creating ACF (aortocaval fistula). Animals were randomized to placebo/MET (300 mg·kg(-1) of body weight·day(-1), 0.5% in food) groups and underwent assessment of metabolism, cardiovascular and mitochondrial functions (n=6-12/group) in advanced HF stage (week 21). A separate cohort served for survival analysis (n=10-90/group). The ACF group had marked cardiac hypertrophy, increased LVEDP (left ventricular end-diastolic pressure) and lung weight confirming decompensated HF, increased circulating NEFAs (non-esterified 'free' fatty acids), intra-abdominal fat depletion, lower glycogen synthesis in the skeletal muscle (diaphragm), lower myocardial triacylglycerol (triglyceride) content and attenuated myocardial (14)C-glucose and (14)C-palmitate oxidation, but preserved mitochondrial respiratory function, glucose tolerance and insulin sensitivity. MET therapy normalized serum NEFAs, decreased myocardial glucose oxidation, increased myocardial palmitate oxidation, but it had no effect on myocardial gene expression, AMPK (AMP-activated protein kinase) signalling, ATP level, mitochondrial respiration, cardiac morphology, function and long-term survival, despite reaching therapeutic serum levels (2.2±0.7 μg/ml). In conclusion, MET-induced enhancement of myocardial fatty acid oxidation had a neutral effect on cardiac function and survival. Recently reported cardioprotective effects of MET may not be universal to all forms of HF and may require AMPK activation or ATP depletion. No increase in mortality on MET supports its safe use in diabetic HF.
650    _2
$a zvířata $7 D000818
650    _2
$a krevní glukóza $x metabolismus $7 D001786
650    _2
$a tělesná hmotnost $x účinky léků $7 D001835
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a preklinické hodnocení léčiv $7 D004353
650    _2
$a glykogen $x metabolismus $7 D006003
650    _2
$a srdeční selhání $x farmakoterapie $x patofyziologie $x ultrasonografie $7 D006333
650    _2
$a hemodynamika $x účinky léků $7 D006439
650    _2
$a hypoglykemika $x krev $x terapeutické užití $7 D007004
650    _2
$a metabolismus lipidů $x účinky léků $7 D050356
650    _2
$a plíce $x patologie $7 D008168
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a metformin $x krev $x terapeutické užití $7 D008687
650    _2
$a srdeční mitochondrie $x fyziologie $7 D008929
650    _2
$a myokard $x metabolismus $x patologie $7 D009206
650    _2
$a velikost orgánu $x účinky léků $7 D009929
650    _2
$a proteinkinasy $x metabolismus $7 D011494
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Wistar $7 D017208
650    _2
$a analýza přežití $7 D016019
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kazdová, Ludmila, $d 1938- $7 xx0053119 $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
700    1_
$a Drahota, Zdeněk, $d 1932- $7 jn20000400531 $u Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic
700    1_
$a Houštěk, Josef, $d 1947- $7 xx0030591 $u Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic
700    1_
$a Medříková, Dáša $7 xx0105138 $u Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic
700    1_
$a Kopecký, Jan, $d 1951- $7 jo20010086901 $u Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic
700    1_
$a Kovarova, Nikola $u Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic
700    1_
$a Vrbacký, Marek $7 xx0128618 $u Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic
700    1_
$a Sedmera, David, $d 1971- $7 xx0037135 $u Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic; Institute of Anatomy, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Strnad, Hynek $7 xx0125779 $u Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic
700    1_
$a Kolář, Michal $7 hka2015854506 $u Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic
700    1_
$a Petrák, Jiří $7 ola2006329820 $u Institute of Pathological Physiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic; Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Benada, Oldřich $7 xx0108253 $u Institute of Microbiology v.v.i., Academy of Sciences of the Czech Republic, Prague, Czech Republic
700    1_
$a Škaroupková, Petra $7 xx0117683 $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
700    1_
$a Červenka, Luděk, $d 1967- $7 xx0037105 $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine (IKEM), Prague; Center for Cardiovascular Research, Prague, Czech Republic; Department of Physiology, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Melenovský, Vojtěch $7 xx0160847 $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic; Center for Experimental Medicine, Institute for Clinical and Experimental Medicine (IKEM), Prague; Center for Cardiovascular Research, Prague, Czech Republic
773    0_
$w MED00009494 $t Clinical science (London, England 1979) $x 1470-8736 $g Roč. 121, č. 1 (2011), s. 29-41
856    41
$u https://pubmed.ncbi.nlm.nih.gov/21275906 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120816 $b ABA008
991    __
$a 20180308091506 $b ABA008
999    __
$a ok $b bmc $g 949131 $s 784435
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2011 $b 121 $c 1 $d 29-41 $i 1470-8736 $m Clinical science (1979) $n Clin Sci (Lond) $x MED00009494
GRA    __
$a NS10497 $p MZ0
LZP    __
$b NLK122 $a Pubmed-20120816/11/02

Najít záznam

Citační ukazatele

Možnosti archivace